Financial Avengers’s Quince Therapeutics QNCX Stock Holding History

Financial Avengers’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$187	–	158
2024 Q4	$187	Hold	1	–	–	﹤0.01%	159
2024 Q3	$78	Hold	1	–	–	﹤0.01%	175
2024 Q2	$75	Hold	1	–	–	﹤0.01%	154
2024 Q1	$109	Hold	1	–	–	﹤0.01%	148
2023 Q4	$105	Hold	1	–	–	﹤0.01%	175
2023 Q3	$112	Hold	1	–	–	﹤0.01%	174
2023 Q2	$151	Hold	1	–	–	﹤0.01%	151
2023 Q1	$156	Hold	1	–	–	﹤0.01%	167
2022 Q4	$64	Hold	1	–	–	﹤0.01%	180
2022 Q3	$0	Hold	1	–	–	﹤0.01%	148
2022 Q2	$0	Hold	1	–	–	﹤0.01%	154
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	143
2021 Q4	$1K	Hold	1	–	–	﹤0.01%	153
2021 Q3	$9K	Hold	1	–	–	0.01%	120
2021 Q2	$5K	Hold	1	–	–	﹤0.01%	139
2021 Q1	$4K	Hold	1	–	–	﹤0.01%	143
2020 Q4	$3K	Buy	+1	New	+$8.86K	﹤0.01%	149

Other funds holding QNCX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Financial Avengers's QNCX Position: Q1 2025 in Review

Financial Avengers sold out of Quince Therapeutics (QNCX) in Q1 2025, closing a stake of 1 share — an estimated $187 sold.

Financial Avengers first reported a position in QNCX in Q4 2020 and held it in 17 quarters. The position peaked at $9K in Q3 2021. 32 funds tracked by Wall St. Rank hold QNCX as of Q1 2025.

Financial Avengers reported no remaining Quince Therapeutics position as of Q1 2025 after selling out during the quarter.
Financial Avengers sold 1 Quince Therapeutics share in Q1 2025, an estimated $187.
Financial Avengers first reported a position in Quince Therapeutics in Q4 2020 and held it in 17 quarters.
Financial Avengers's Quince Therapeutics position peaked at $9K in Q3 2021.
32 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2025.

Based on Financial Avengers's 13F filing for Q1 2025, filed 15 May 2025.